Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016

被引:6
作者
Mukherjee, Kumar [1 ]
Small, William, Jr. [2 ]
Duszak, Richard, Jr. [3 ]
机构
[1] Philadelphia Coll Osteopath Med, 625 Old Peachtree Rd NW, Suwanee, GA 30024 USA
[2] Loyola Univ Chicago, Stritch Sch Med, Dept Radiat Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[3] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA
关键词
Radiotherapy; Brachytherapy; Intensity modulated radiation therapy; SEER; Medicare; Cost of radiotherapy; Utilization of radiotherapy; Prostate Cancer; INTENSITY-MODULATED RADIOTHERAPY; CONFORMAL RADIATION-THERAPY; PROTON THERAPY; BRACHYTHERAPY; OUTCOMES; MEN; ADENOCARCINOMA; REIMBURSEMENT; POPULATION; MANAGEMENT;
D O I
10.1016/j.brachy.2021.06.148
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE: To assess recent changes and disparities in utilization and costs of radiotherapy in Medicare beneficiaries with prostate cancer. METHODS: Surveillance, Epidemiology and End Results (SEER) -Medicare linked data from 2006-2016 were used to identify continuously enrolled Medicare beneficiaries with a first-time diagnosis of prostate cancer who, within 12 months of diagnosis, underwent at least one radiotherapy related service. Trends in the utilization of different radiotherapy techniques over time, yearly changes in per-patient costs of radiotherapy, and effect of socio-demographic and clinical characteristics on total cost were measured. Per patient annual costs, annual incidence of prostate cancer, and utilization of radiotherapy were used to estimate total costs of radiotherapy to the Medicare program. RESULTS: For Medicare beneficiaries with a first-time diagnosis of prostate cancer, the utilization of intensity modulated radiation therapy (IMRT), proton therapy, and stereotactic body radiation therapy (SBRT) increased 23.62%, 0.74% and 1.61% respectively ( p < 0.0001) while brachytherapy decreased 17.04% ( p < 0.0001). Cost per beneficiary decreased $340.24 (95% CI: $136.05 -$544.43) annually ( p = 0.0065). Age, registry region, and Gleason score were all associated with expenditures. The total cost to the Medicare program was estimated at US $1.16 billion in the year 2016. DISCUSSION: In Medicare beneficiaries with prostate cancer treated with radiotherapy, IMRT is the primary mode of treatment. Utilization of brachytherapy decreased significantly despite the efficacy and cost-effectiveness. Although per patient costs have decreased, the share of patient responsibility remained unaltered across years. The current costs to Medicare of radiotherapy for newly diagnosed prostate cancer patients is substantial. (C) 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:12 / 21
页数:10
相关论文
共 50 条
  • [1] Agency for Healthcare Research and Quality, US APPR PRIC IND AN
  • [2] The Sources of the SGR "Hole"
    Alhassani, Ali
    Chandra, Amitabh
    Chernew, Michael E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04) : 289 - 291
  • [3] Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013
    Amin N.P.
    Sher D.J.
    Konski A.A.
    [J]. Applied Health Economics and Health Policy, 2014, 12 (4) : 391 - 408
  • [4] [Anonymous], 2018, SEER*Stat Database: Incidence-SEER Research Data, 18 Registries Custom Data [with additional treatment fields]
  • [5] Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival
    Bechis, Seth K.
    Carroll, Peter R.
    Cooperberg, Matthew R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 235 - 241
  • [6] Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men
    Borza, Tudor
    Kaufman, Samuel R.
    Shahinian, Vahakn B.
    Yan, Phyllis
    Miller, David C.
    Skolarus, Ted A.
    Hollenbeck, Brent K.
    [J]. HEALTH AFFAIRS, 2017, 36 (01) : 108 - 115
  • [7] Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database
    Burt, Lindsay M.
    Shrieve, Dennis C.
    Tward, Jonathan D.
    [J]. ADVANCES IN RADIATION ONCOLOGY, 2018, 3 (02) : 170 - 180
  • [8] Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
    Chen, Ronald C.
    Rumble, R. Bryan
    Loblaw, D. Andrew
    Finelli, Antonio
    Ehdaie, Behfar
    Cooperberg, Matthew R.
    Morgan, Scott C.
    Tyldesley, Scott
    Haluschak, John J.
    Tan, Winston
    Justman, Stewart
    Jain, Suneil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18) : 2182 - +
  • [9] Trends in Management for Patients With Localized Prostate Cancer, 1990-2013
    Cooperberg, Matthew R.
    Carroll, Peter R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (01): : 80 - 82
  • [10] Variation in Treatment Associated With Life Expectancy in a Population-Based Cohort of Men With Early-Stage Prostate Cancer
    Daskivich, Timothy J.
    Lai, Julie
    Dick, Andrew W.
    Setodji, Claude M.
    Hanley, Janet M.
    Litwin, Mark S.
    Saigal, Christopher
    [J]. CANCER, 2014, 120 (23) : 3642 - 3650